Oral mucositis—case series of a rare adverse effect associated with immunotherapy

Sheth, Hardik; Pragya, Ramya; Kovale, Shama; Deshpande, Mandar; Mistry, Rajesh; Shreenivas, Aditya; Limaye, Sewanti

doi:10.1007/s00520-021-05993-5

Cited by 10 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining 408 were screened for titles and abstracts, of which 53 were read in full. Finally, 35 articles 8,11–44 were included in this study since they met the eligibility criteria (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…After a careful reading of the studies, only of those whose primary objective was the association between ICIs and oral manifestations were definitely included. 13.0 (Search Technology, Inc.). The following information were extracted and evaluated from all studies included to perform the bibliometric analysis: title, keywords, type of study, ICI used, country of origin, year of publication, authors, main authors (most prolific, with two or more articles published) and collaborations between authors, journals and main journals (with two or more publications).…”

Section: Data Extractionmentioning

confidence: 99%

See 1 more Smart Citation

Lesions in the oral mucosa associated with the use of checkpoint inhibitors: A bibliometric and critical review

Jural,

Estanho,

Pereira

et al. 2023

Special Care in Dentistry

View full text Add to dashboard Cite

AimsImmune‐related adverse events (irAEs) linked to the use of immune checkpoint inhibitors (ICIs) have become increasingly frequent. To perform a bibliometric and critical review of the general panorama of publications on oral mucosal lesions (OML) associated with ICIs.Methods and ResultsSystematized searches were performed in four databases. The included studies were organized and bibliometric and clinical data were extracted and analyzed using VantagePoint and Microsoft Excel. Most of the 35 included studies were reports or case series (n = 33/94.2%). The American authors stood out (n = 17/48.5%), with the majority presenting only one publication. Independent groups carried out most of the publications (n = 31/88.5%). Over the years, publications have increased for users of nivolumab and pembrolizumab. In 21 studies (60%), OML were more common in men, between the 6th and 9th decades of life and who had lung carcinoma (n = 13/37.1%). Pembrolizumab (n = 17/48.5%) was the most used ICI. The patients were affected by one or more OML, including: ulcers (n = 28/80%) and erythema (n = 11/31.4%). Systemic corticosteroids (n = 24/68.5%) and the discontinuation of ICI use (n = 18/51.4%) were the main approaches used.ConclusionOML related to the use of ICIs have become increasingly common. More accurate data need to be published.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Data Extractionmentioning

confidence: 99%

Lesions in the oral mucosa associated with the use of checkpoint inhibitors: A bibliometric and critical review

Jural,

Estanho,

Pereira

et al. 2023

Special Care in Dentistry

View full text Add to dashboard Cite

show abstract

“…The clinical presentations vary according to the types of the inhibitors 16–18 . Although immunotherapy‐related mucosal injury has not been adequately reported, reports on anti‐programmed cell death protein‐1/programmed cell death ligand 1 (anti–PD‐1/PD‐L1) agents suggest that oral lichenoid reactions could be the most common mucosal injuries, which are possibly caused by infiltration of normal mucosa with activated T cells 19–21 …”

Section: Discussionmentioning

confidence: 99%

“…[16][17][18] Although immunotherapy-related mucosal injury has not been adequately reported, reports on anti-programmed cell death protein-1/programmed cell death ligand 1 (anti-PD-1/PD-L1) agents suggest that oral lichenoid reactions could be the most common mucosal injuries, which are possibly caused by infiltration of normal mucosa with activated T cells. [19][20][21] As evidences accumulate, organizations such as MASCC/ISOO and European Society for Medical Oncology (ESMO) are continuously updating guidelines for CMI. 22,23 The management of mucosal injury induced by targeted therapies and immunotherapies is currently based on the experts' opinions.…”

Section: Coupling Analysismentioning

confidence: 99%

Cancer‐therapy‐induced mucosal injury from 2001 to 2021: A bibliometric analysis

Qiu

Zhang

et al. 2022

J Oral Pathology Medicine

View full text Add to dashboard Cite

Background: Cancer-therapy-induced mucosal injury (CMI) is a common and deleterious complication that affects patients undergoing cancer therapies. This study was aimed at elucidating knowledge bases and predicting research trends of this field, by analyzing the bibliographic data of CMI. Methods: The bibliographic data of CMI from 2001 to 2021 were extracted from the Web of Science Core Collection database in March 2022. After screening, a total of 8181 articles and reviews were included in the study. CiteSpace and VOSviewer were applied to analyze and visualize cooperation, cooccurrence, cocitation, and coupling networks.

show abstract

“…Thus, cases occurring upwards of 1 year following initiation of therapy may warrant consideration of an unrelated disease process. Furthermore, in both clinical practice and clinical trials, oral irAEs, particularly those characterized by oral ulcers, are often termed “mucositis” or “stomatitis,” which are non‐specific diagnoses (Acero Brand et al, 2018; Cao et al, 2017; Lederhandler et al, 2018; Sheth et al, 2021; Wongvibulsin et al, 2021). This lack of specificity and the potential for overlapping features underscore the need for management guidelines that approach these reactions based on both clinical presentation and severity.…”

Section: Discussionmentioning

confidence: 99%

Oral manifestations of immune‐related adverse events in cancer patients treated with immune checkpoint inhibitors

et al. 2021

View full text Add to dashboard Cite

Immunotherapy with immune checkpoint inhibitors (ICIs) has transformed cancer treatment over the past decade, improving survival rates in numerous advanced cancers. Immune-related adverse events (irAEs) are common and can affect any organ system, with many of these toxicities being well-characterized with clear grading criteria and management approaches. There has been less emphasis on oral manifestations of irAEs. This review provides an overview of oral manifestations of irAEs, including mucosal and salivary gland toxicities, and proposes a grading system and management guidelines. irAEs are common treatment-related toxicities in patients treated with ICIs. Oral irAEs can range from asymptomatic white reticulations to life-threatening mucocutaneous reactions requiring aggressive management with corticosteroids and/or permanent discontinuation of ICIs. Oral healthcare providers should be prepared to identify and manage oral irAEs in collaboration with oncologists and other specialists.

show abstract

Oral mucositis—case series of a rare adverse effect associated with immunotherapy

Cited by 10 publications

References 18 publications

Lesions in the oral mucosa associated with the use of checkpoint inhibitors: A bibliometric and critical review

Lesions in the oral mucosa associated with the use of checkpoint inhibitors: A bibliometric and critical review

Cancer‐therapy‐induced mucosal injury from 2001 to 2021: A bibliometric analysis

Oral manifestations of immune‐related adverse events in cancer patients treated with immune checkpoint inhibitors

Contact Info

Product

Resources

About